Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Currently in Phase 1 testing, KT-621 has demonstrated dupilumab-like activity and very ... Leveraging its proven small molecule discovery capabilities, deep expertise, and unique target selection ...

Currently in Phase 1 testing, KT-621 has demonstrated dupilumab-like activity and very ... Leveraging its proven small molecule discovery capabilities, deep expertise, and unique target selection ...

So, A, the form of a smoker story is pretty interesting from our perspective and orthogonal to dupilumab ... people that were the custodians of the molecule in [indiscernible] in Cambridge ...

Ebglyss, the third biologic targeting IL-13 for atopic dermatitis, follows Dupixent (dupilumab) and Adbry/Adtralza (tralokinumab ... lowering therapy based on a double-stranded RNA molecule, pending ...

EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab ... therapy based on a double-stranded RNA molecule, pending approval. GSK plc's GSK-3536819 ...

The drug provides both bronchodilation and anti-inflammatory properties in a single molecule and is administered ... IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the lung ...

According to the report, fitusiran could become the first antithrombin-lowering therapy based on a double-stranded RNA molecule, pending approval, and has a sales prediction of $1 billion.

Currently in Phase 1 testing, KT-621 has demonstrated dupilumab-like activity and very good safety ... Leveraging its proven small molecule discovery capabilities, deep expertise, and unique target ...

EBGLYSS, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT (dupilumab) and ADBRY/ADTRALZA (tralokinumab ... lowering therapy based on a double-stranded RNA molecule, pending ...